ADME/PK as part of a rational approach to drug discovery

Drug Discovery Today

Volumn 5, Issue 9, 2000, Pages 409-414

  Eddershaw, Peter J ^a   Beresford, Alan P ^a   Bayliss, Martin K ^a  

^a GLAXOSMITHKLINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG;

AUTOMATION; DRUG ABSORPTION; DRUG DESIGN; DRUG DISTRIBUTION; DRUG EXCRETION; DRUG METABOLISM; DRUG RESEARCH; REVIEW; TECHNOLOGY;

EID: 0034283752     PISSN: 13596446     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1359-6446(00)01540-3     Document Type: Review

References (28)

1. Kennedy A. Managing the drug discovery/development interface. Drug Discovery Today. 2:1997;436-444.
2. Prentis R.A. et al. Pharmaceutical innovation by the seven UK-owned pharmaceutical companies (1964-1985). Br. J. Clin. Pharmacol. 25:1988;387-396.
3. Crespi C.L. et al. Microtiter plate assays for inhibition of human, drug-metabolizing cytochromes P450. Anal. Biochem. 248:1997;188-190.
4. Moody G.C. et al. Fully automated analysis of activities catalysed by the major human liver cytochrome P450 (CYP) enzymes: assessment of human CYP inhibition potential. Xenobiotica. 29:1999;53-75.
5. Caldwell G.W. Compound optimization in early- and late-phase drug discovery: acceptable pharmacokinetic properties utilizing combined physicochemical, in vitro and in vivo screens. Curr. Opin. Drug Discov. 3:2000;30-41.
6. Sinko P.J. Drug selection in early drug development: screening for acceptable pharmacokinetic properties using combined in vitro and computational approaches. Curr. Opin. Drug Discov. 2:1999;42-48.
7. Bertz R.J., Granneman G.R. Use of in vitro and in vivo data to estimate the likelihood of metabolic pharmacokinetic interactions. Clin. Pharmacokinet. 32:1997;210-258.
8. Krzyzanski W., Jusko W.J. Characterization of pharmacodynamic recession slopes for direct and indirect response models. J. Pharmacokinetics Biopharm. 26:1998;409-436.
9. Sharma A., Jusko W.J. Characteristics of indirect pharmacodynamic models and applications to clinical drug responses. Br. J. Clin. Pharmacol. 45:1998;229-239.
10. Rodrigues A.D. Preclinical drug metabolism in the age of high-throughput screening: an industrial perspective. Pharm. Res. 14:1997;1504-1510.
11. Smith D.A. et al. Design of drugs involving the concepts and theories of drug metabolism and pharmacokinetics. Med. Res. Rev. 16:1996;243-266.
12. Frick L.W. et al. Cassette dosing: rapid in vivo assessment of pharmacokinetics. Pharm. Sci. Technol. Today. 1:1998;12-18.
13. Watt A.P. et al. Approaches to higher-throughput pharmacokinetics (HTPK) in drug discovery. Drug Discovery Today. 5:2000;17-24.
14. Artursson P., Borchardt R.T. Intestinal drug absorption and metabolism in cell cultures: Caco-2 and beyond. Pharm. Res. 14:1997;1655-1658.
15. Lu A.Y.H. Applications and limitations of interspecies scaling and in vitro extrapolation in pharmacokinetics. Drug Metab. Dispos. 26:1998;1202-1212.
16. Chong S. et al. In vitro permeability through Caco-2 cells is not quantitatively predictive of in vivo absorption for peptide-like drugs absorbed via the dipeptide transporter system. Pharm. Res. 13:1996;120-123.
17. Obach R.S. Prediction of human clearance of twenty-nine drugs from hepatic microsomal intrinsic clearance data: an examination of in vitro half-life approach and nonspecific binding to microsomes. Drug Met. Dispos. 27:1999;1350-1359.
18. Eddershaw P.J., Dickins M. Advances in in vitro drug metabolism screening. Pharm. Sci. Technol. Today. 2:1999;13-19.
19. Wrighton S.A. et al. In vitro methods for assessing human hepatic drug metabolism: their use in drug development. Drug Metab. Rev. 25:1993;453-484.
20. Irvine J.D. et al. MDCK (Madin-Darby canine kidney) cells: a tool for membrane permeability screening. J. Pharm. Sci. 88:1999;28-33.
21. el Hafny B. et al. Synergistic stimulation of gamma-glutamyl transpeptidase and alkaline phosphatase activities by retinoic acid and astroglial factors in immortalized rat brain microvessel endothelial cells. J. Cell. Physiol. 167:1996;451-460.
22. Hurst R.D., Fritz I.B. Properties of an immortalised vascular endothelial/glioma cell co-culture model of the blood-brain barrier. J. Cell. Physiol. 167:1996;81-94.
23. Mandagere A.K. et al. Application of automation to Caco-2 drug diffusion studies. Pharmacol. Res. 13:1996;S237.
24. Walters W.P. et al. Virtual screening - an overview. Drug Discovery Today. 3:1998;160-178.
25. Hansch C., Zhang L. Quantitative structure-activity relationships of cytochrome P-450. Drug Metab. Rev. 25:1993;1-48.
26. Smith D.A. Design of drugs through a consideration of drug metabolism and pharmacokinetics. Eur. J. Drug Metab. Pharmacokinet. 1994;193-199.
27. Lipinski C.A. et al. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Deliv. Rev. 23:1997;3-25.
28. Clark D.E., Pickett S.D. Computational methods for the prediction of `drug-likeness'. Drug Discovery Today. 2:2000;49-58.